- Home
- GLAS vs KURA Comparison
GLAS vs KURA Comparison
Compare GLAS & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLAS | KURA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.5M | 1.1B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GLAS | KURA |
|---|---|---|
| Price | $9.93 | $12.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 329.3K | ★ 1.8M |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $9.12 | $7.36 |
| 52 Week High | $12.70 | $12.90 |
Technical Indicators
Market Signals| Indicator | GLAS | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 58.47 |
| Support Level | $9.22 | $7.71 |
| Resistance Level | $10.42 | $12.34 |
| Average True Range (ATR) | 0.56 | 0.59 |
| MACD | 0.04 | 0.23 |
| Stochastic Oscillator | 47.62 | 62.41 |
Price Performance
Historical ComparisonAbout GLAS Glass House Brands Inc. Subordinate Voting Shares
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.